<?xml version="1.0" encoding="UTF-8"?>
<p>Oral pre-exposure prophylaxis (PrEP) with daily tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) by HIV-negative people can prevent contracting HIV and is a key intervention that can support reducing HIV infections by 90% by 2030. Initially, in 2012, the World Health Organization (WHO) recommended PrEP for special populations such as sero-discordant couples (SDCs), men who have sex with men (MSM), and transgender women who have sex with men [
 <xref rid="pone.0227632.ref001" ref-type="bibr">1</xref>â€“
 <xref rid="pone.0227632.ref004" ref-type="bibr">4</xref>]. However, in 2015, WHO expanded their recommendation to include all population groups at substantial risk of HIV infection as part of a comprehensive package of HIV prevention interventions [
 <xref rid="pone.0227632.ref005" ref-type="bibr">5</xref>]. The UNAIDS fast track programme identified Zimbabwe as one of the countries that contributes to 89% of new HIV infections globally [
 <xref rid="pone.0227632.ref006" ref-type="bibr">6</xref>]. These countries are encouraged to take up new innovations such as PrEP in order to meet their 95-95-95 targets by 2030 and reduce the number of new infections. Zimbabwe has a generalized epidemic [
 <xref rid="pone.0227632.ref007" ref-type="bibr">7</xref>] and would benefit from offering comprehensive HIV prevention and treatment services to the general population.
</p>
